Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Patented case on November 8, 2023 - 🇺🇲 US16/983,300: "Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines"
$NWBO patented case on November 8, 2023 - 🇺🇲 US16/983,300: "Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines"https://t.co/Tr7fEnYZ7B pic.twitter.com/32uiRzjGbH
— Henry (@HenryMuney) November 8, 2023
Another Flaskworks patented case today, "Duty Cycle for Cell Culture Systems"
#Flaskworks patented case on January 11, 2023: US16/539,916 - "Duty Cycle for Cell Culture Systems" $NWBOhttps://t.co/b5at8ys9m2 pic.twitter.com/gtAGRMo8da
— Henry (@HenryMuney) January 11, 2023
Radiation Oncology Invited Speaker Seminar Series - Linda M. Liau, MD, PhD Thursday, October 27th, 2022
https://www.med.upenn.edu/radiationoncologymedicalresidency/
Patent granted on July 15, 2022 for MX/a/2018/003197 ???? - Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
1. https://vidoc.impi.gob.mx/DocVidoc.aspx?param=yWmOEtsT7jnuseUu9PjM0HojOoSkFfDU
2. https://patentscope.wipo.int/search/en/detail.jsf?docId=MX234853107
3.
$NWBO Patent granted on July 15, 2022 for MX/a/2018/003197 🇲🇽 - Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
— Henry (@HenryMuney) August 2, 2022
1. https://t.co/eImO2MqVdL
2. https://t.co/kmm9jINl1Q pic.twitter.com/1jq2XNJIpm
Patent granted on August 2, 2022 by Israel: IL245337 - "Combinations of checkpoint inhibitors and therapeutics to treat cancer"
1. https://israelpatents.justice.gov.il/en/patent-extract/245337
2. https://patentscope.wipo.int/search/en/detail.jsf?docId=IL175226722
3.
$NWBO Patent granted on August 2, 2022 by Israel: IL245337 - "Combinations of checkpoint inhibitors and therapeutics to treat cancer"
— Henry (@HenryMuney) August 2, 2022
1. https://t.co/WPzawT3tFX
2. https://t.co/1GlM7r6TgO pic.twitter.com/FGWt4qcjJR
Flaskworks patent application status "Issue Fee Payment Received" on July 27, 2022: US17/074,970 - Systems and Methods for Cell Culturing". Next step, patent issuance.
NOTE: This is not the same application as posted yesterday - US17/074,944.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US322187586
#Flaskworks patent application status "Issue Fee Payment Received" on July 27, 2022: US17/074,970 - "Systems and Methods for Cell Culturing". Next step, patent issuance. $NWBO
— Henry (@HenryMuney) July 27, 2022
NOTE: This is not the same application as posted yesterday - US17/074,944.https://t.co/q8AR85Spgb pic.twitter.com/5JCIMqsCkk
Flaskworks patent application status "Issue Fee Payment Received" on July 26, 2022: US17/074,944 - Systems and Methods for Cell Culturing".
https://patentscope.wipo.int/search/en/detail.jsf?docId=US322187585
#Flaskworks patent application status "Issue Fee Payment Received" on July 26, 2022: US17/074,944 - Systems and Methods for Cell Culturing". $NWBO
— Henry (@HenryMuney) July 27, 2022
Next step, patent issuance.https://t.co/DXqSMIPPGK pic.twitter.com/OhmGGIix8k
Patent issuance fee payment made on July 15, 2022 for MX/a/2018/003197 (Mexico) - Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
Next step is patent issuance.
1. https://vidoc.impi.gob.mx/DocVidoc.aspx?param=pziuyisgIDk17meQG+rMywkjUkHfhlUJ
2. https://patentscope.wipo.int/search/en/detail.jsf?docId=MX234853107
$NWBO Patent issuance fee paid on July 15, 2022 for MX/a/2018/003197 🇲🇽 - Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
— Henry (@HenryMuney) July 19, 2022
Next, patent issuance.
1. https://t.co/JrcFuSgZBH
2. https://t.co/kmm9jJ4VTo pic.twitter.com/vzBxvcqUys
Thanks flipper44. While on the topic of patents, there was a recent notice of publication on a different patent on May 12, 2022, "Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response".
Published May 12, 2022:
https://patentscope.wipo.int/search/en/detail.jsf?docId=US360588178
The previously issued patent (granted Sept 21, 2021) that is in the same family is at:
https://patentscope.wipo.int/search/en/detail.jsf?docId=US222843583
It appears there are more claims on the recently published patent application. Also, if you're willing to discuss about more $NWBO and/or Flaskworks patents, please reach out to @henrymuney on Twitter or let me know how I can contact you directly.
26 patients with malignant glioma
For exwannabe: Yes, read the application withdrawal letter. Did you read the application details too? I think some other context was missed in your reply.
https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/sitoiganap
*What did the company present to support its application?
The company presented the results of one main study involving 26 patients with malignant glioma, where Sitoiganap was compared with placebo (a dummy treatment), both taken with bevacizumab (another cancer medicine). Patients who received Sitoiganap plus bevacizumab were also given GM-CSF and cyclophosphamide (two medicines to stimulate the immune response). The main measures of effectiveness were how long the patients lived and how long the patients lived without their disease getting worse.
*What did the Agency recommend at that time?
Based on the review of the available information, at the time of the withdrawal, the Agency had concerns and its provisional opinion was that Sitoiganap could not have been authorised for the treatment of glioma.
The Agency had concerns about the way the medicine was produced and the documentation describing the manufacturing process, leading to uncertainties about the quality of the medicine. The Agency also considered that the non-clinical studies did not demonstrate how the medicine is supposed to work in patients with glioma. Adding to these concerns, the results of the main study were not robust enough to show that Sitoiganap was effective at treating patients with glioma, and the safety profile of the medicine could not be established.
Therefore, at the time of the withdrawal, the Agency was not able to draw conclusions on the effectiveness of Sitoiganap in treating glioma and its opinion was that the benefits of Sitoiganap in this use did not outweigh its risks.
To close the loop on Sitoiganap (or Gliovac), it appears the marketing authorization application was withdrawn on May 2, 2022.
Product number: EMEA/H/C/003693
Application Details: https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/sitoiganap
Withdrawal Letter: https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sitoiganap_en.pdf
International Non-proprietary Name (INN): Autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogenei
Dr. Phioanh Leia Nghiemphu, Professor and Vice Chair of Academic Affairs at the UCLA Dept of Neurology mentioned, "There are various vaccines that have been in clinical trials. Here at UCLA we use a DCVax..."
Dr. Nghiemphu mentioned DCVax 3 times in the presentation at the 2022 UCLA Brain Tumor Virtual Conference on May 6, 2022. The YT video was posted on May 31, 2022.
1.
Dr. Phioanh Leia Nghiemphu, Professor and Vice Chair of Academic Affairs at @UCLANeurology mentioned, "There are various vaccines that have been in clinical trials. Here at UCLA we use a DCVax..."
— Henry (@HenryMuney) June 3, 2022
1. https://t.co/HaHBM6Jofw
2. https://t.co/8Aw3BjVPhy#DCVax-L $NWBO pic.twitter.com/ApJYoKJod0
Confirming the issuance (May 24, 2022) of Flaskworks patent US16/841,197 - Dendritic Cell Generating Apparatus and Method
https://patentscope.wipo.int/search/en/detail.jsf?docId=US300129019
Update: Flaskworks "Patented Case" on May 4, 2022: US16/841,197 - Dendritic Cell Generating Apparatus and Method
1.
Update: Flaskworks "Patented Case" on May 4, 2022: US16/841,197 - Dendritic Cell Generating Apparatus and Method $NWBO #Flaskworks #DCVaxhttps://t.co/ydOvGYGy6p@biggercapital @rago_carlo @ATLnsider @joanlappin @FlemmingBruce @metacollectiveG pic.twitter.com/zQzMkXgXFI
— Henry (@HenryMuney) May 4, 2022
Patent application with status "Acceptance of application" on April 30, 2022 by Israel: IL245337 - "Combinations of checkpoint inhibitors and therapeutics to treat cancer"
1.
$NWBO patent application with status "Acceptance of application" on April 30, 2022 by Israel: IL245337 - "Combinations of checkpoint inhibitors and therapeutics to treat cancer"
— Henry (@HenryMuney) May 2, 2022
1. https://t.co/WPzawSLShn
2. https://t.co/1GlM7qPhSe@biggercapital @rago_carlo @ATLnsider pic.twitter.com/TuxENJUm02
Flaskworks patent application status "Mail Notice of Allowance" on April 28, 2022: US17/074,970 - Systems and Methods for Cell Culturing". NOTE: US17/074,970 is not the same application as posted yesterday - US17/074,944.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US322187586
Flaskworks patent application status "Mail Notice of Allowance" on April 27, 2022: US17/074,94 - Systems and Methods for Cell Culturing. As usual, now all that's left is paying the issue fee to seal the patent issuance.
Flaskworks patent application status "Mail Notice of Allowance" on April 27, 2022: US17/074,94 - Systems and Methods for Cell Culturing. As usual, now all that's left is paying the issue fee to seal the patent issuance. #Flaskworks $NWBOhttps://t.co/DXqSMIPPGK@biggercapital pic.twitter.com/DeoAqdjV26
— Henry (@HenryMuney) April 27, 2022
"Issue Fee Payment" on April 19, 2022 (US16/841,197 - Dendritic Cell Generating Apparatus and Method). Issuance bill was paid today. Now we just wait for patent issuance.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US300129019
Linda Liau is a Speaker at Frontiers in Cancer Immunotherapy 2022 at the NY Academy of Sciences.
May 10 at 11:10AM ET - "Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma"
https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/websitePage:ccf12eed-4b47-487c-82af-faa589df6e0a
Reposting the above to clarify that LL is a "Speaker"
My mistake while reading too early in the AM on my mobile device! I'll update my Tweet to note that she is a "Speaker" and not a "Keynote Speaker". I prefer keeping my posts factual, so honest mistake. Thanks for letting me know!
LL is a Keynote Speaker at Frontiers in Cancer Immunotherapy 2022 at the NY Academy of Sciences.
Dr. Linda Liau MD, PhD is a Keynote Speaker at Frontiers in Cancer Immunotherapy 2022 at the NY Academy of Sciences.
— Henry (@HenryMuney) April 15, 2022
May 10 at 11:10AM ET - "Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma"https://t.co/LjNhhhQ5HU$NWBO @biggercapital @rago_carlo pic.twitter.com/k5xEhhHtoc
Dr. Linda Liau today, Thursday, March 31, 2022 5:00PM - 6:00PM (EDT). "Overcoming the Challenges in Brain Cancer Therapy"
https://umiamihealth.org/sylvester-comprehensive-cancer-center/research/education-and-training/events-calendar/class-details?id=bca25d12-eabc-4d16-8247-b36f1e3bd1ce
EU patent granted on 3/17/2022 (effective on 4/13/2022): EP3350318 - Methods Relating To Activated Dendritic Cell Compositions For Subjects With Advanced Cancers
https://register.epo.org/application?number=EP16847253
Flaskworks patent issue date on March 8, 2022: US17/074,893 - Systems And Methods For Cell Culturing.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US322187583
Flaskworks patent application status with "Issue Fee Payment Received" on February 1, 2022: US17/074,893 - Systems And Methods For Cell Culturing. About ~4 weeks to issuance.
1. https://patentscope.wipo.int/search/en/detail.jsf?docId=US322187583
2. https://www.uspto.gov/web/offices/pac/mpep/s1306.html#d0e133566
Patent issued by Canada on January 11, 2022 (as anticipated): CA2632263 - Compositions and Methods for Inducing the Activation of Immature Monocytic Dendritic Cells
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2632263/summary.html?query=2632263&type=basic_search
Another patent granted on November 30, 2021 by Japan: JP6985939 (Publication Number: JP2018523996) - OPTIMALLY ACTIVATED DENDRITIC CELLS THAT INDUCE AN IMPROVED OR ENHANCED ANTITUMOR IMMUNE RESPONSE
https://www.j-platpat.inpit.go.jp/?uri=/c1800/PU/JP-6985939/1E0A72A9D7037797BFA3BCF2D875FA9D87266DB70853D5E4C56BCAB27BBC9866/15/en
A $NWBO patent application status with "Notice of Allowance" on July 22, 2021, "Final Fee" paid on November 19, 2021, and "Forecasted Issue Date" on January 11, 2022: CA2632263 (Canada) - Compositions And Methods For Inducing The Activation Of Immature Monocytic Dendritic Cells
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2632263/summary.html?query=2632263
A patent granted on August 3, 2021 by Canada: CA2490245 - Tangential Flow Filtration Devices And Methods For Leukocyte Enrichment
1. https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2490245/summary.html
2. https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2490245/images.html?frenchDocType=Correspondance&englishDocType=Correspondence&modificationDate=20201203&page=1&scale=25&rotation=0&type=&objectName=A1001001A21H03A91903F75158&numPages=1
3. Maintenance paid on 12/17/2021: https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2490245/images.html?frenchDocType=Taxes&englishDocType=Fees&modificationDate=20201217&page=1&scale=25&rotation=0&type=&objectName=A1001001A21L17B93009B80615&numPages=1
A patent granted on November 19, 2021 by Japan: JP2018513634 - ACTIVATED DENDRITIC CELL COMPOSITION FOR SUBJECTS WITH ADVANCED CANCER AND METHODS FOR IMMUNOTHERAPEUTIC TREATMENT
https://www.j-platpat.inpit.go.jp/c1800/PU/JP-2018-513634/55F5FFCC0DD99FEC309B8A87303816EB7A0739B18AFECFA33971197848A73880/10/en
A patent granted on September 30, 2021 by Israel: IL258071 - Methods Relating To Activated Dendritic Cell Compositions And Immunotherapeutic Treatments For Subjects With Advanced Cancers
https://israelpatents.justice.gov.il/en/patent-extract/258071
A patent granted on June 16, 2021 by the Russian Federation:
RU0002749610 - Methods Related To Activated Dendritic Cells Compositions and To Immunotherapeutic Treatment of Individuals With Advanced Cancer
https://new.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2749610&TypeFile=html
On another patent, $NWBO's patent attorney mentioned twice, "for the sake of procedural expediency" in response to the European Patent Office (Oct 4, 2021).
EP3650110 - Tangential Flow Filtration Device and Methods for Leukocyte Enrichment: https://register.epo.org/application?number=EP19194995&lng=en&tab=main
Patent publication JP2021045176A (Japan) on 3/25/2021 - "Compositions and Methods for Inducing Activation of Immature Monocyte Dendritic Cells".
1. https://www.j-platpat.inpit.go.jp/s0100 search for ??????? ????????????, ??????????
2. https://patents.google.com/patent/JP2021045176A/en
Another GoFundMe page mentioning the DCVax-L and Keytruda combo trial.
August 8, 2021 by Alyssa Bernhardt, Organizer:
"On Friday, Jenn received her third and final set of vaccines in the clinical trial. She will continue to receive the immunotherapy infusion every 6 weeks at UCLA. There has been recent positive news from other cancer vaccine trials. Still some obstacles to overcome and even if you can’t help financially, please keep Jenn in your thoughts and send all the good vibes.
More info from Jenn about the trial and vaccine:
The trial has 3 components. 1. Surgery 2. Personalized vaccine made with my tumor cells (you can google DCVAX If you want to know more!) 3. An immunotherapy drug called Keytruda (it’s possible that I will be in the control group and only receive a placebo)."
https://www.gofundme.com/f/jennifershepherd
Flaskworks patent publication IL283074D0 (Israel) on 6/29/2021 titled "Dendritic cell generating apparatus and method".
1. https://israelpatents.justice.gov.il/en/patent-extract/283074
2. https://israelpatents.justice.gov.il/en/search?FTS_0_option=FreeAny&FTS_0_0=flaskworks
3. https://patents.google.com/patent/IL283074D0/en
Linda Liau at the SNI Neurosurgery World Education Summit on 6/5:
https://www.snidigital.org/schedule
Flaskworks patent applications published recently. Shashi Murthy has been busy with patent applications. Not sure if these were mentioned yet.
4/29 (International): https://patents.google.com/patent/WO2021080847A1
4/22 (US): https://patents.google.com/patent/US20210115374A1
$NWBO confirmed as online exhibitor at ASCO 2021
$NWBO is an online exhibitor at the 2021 ASCO Annual meeting. Online Exhibitor List updated as of May 13th, 2021. https://t.co/e7b3ZUyVTthttps://t.co/gTFRwGtgqC#DCVax-L #ASCO2021 pic.twitter.com/lTCHX13b4c
— Henry (@HenryMuney) May 13, 2021
WO2021071977A1 Recent international patent application published 4/15:
https://patents.google.com/patent/WO2021071977A1/en